Flexion Therapeutics (FLXN) Raised to “Sell” at BidaskClub

BidaskClub upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a strong sell rating to a sell rating in a research note published on Friday morning.

Several other equities analysts have also commented on FLXN. ValuEngine lowered Flexion Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, June 27th. Benchmark assumed coverage on Flexion Therapeutics in a research report on Thursday, June 28th. They set a buy rating and a $39.00 price objective for the company. Finally, Zacks Investment Research lowered Flexion Therapeutics from a buy rating to a hold rating in a research report on Monday, August 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Flexion Therapeutics presently has a consensus rating of Buy and a consensus price target of $37.86.

Flexion Therapeutics stock traded down $0.19 on Friday, hitting $18.38. 810,627 shares of the stock traded hands, compared to its average volume of 601,261. The company has a current ratio of 12.90, a quick ratio of 12.78 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $707.53 million, a P/E ratio of -4.42 and a beta of 0.74. Flexion Therapeutics has a 1 year low of $17.26 and a 1 year high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.06. The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $3.96 million. Analysts predict that Flexion Therapeutics will post -4.75 earnings per share for the current year.

In related news, CEO Michael D. Clayman purchased 10,000 shares of the stock in a transaction dated Thursday, August 9th. The stock was purchased at an average price of $22.33 per share, with a total value of $223,300.00. Following the transaction, the chief executive officer now directly owns 75,282 shares in the company, valued at $1,681,047.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David Arkowitz purchased 4,000 shares of the stock in a transaction dated Thursday, August 9th. The stock was bought at an average cost of $23.42 per share, with a total value of $93,680.00. Following the transaction, the chief financial officer now owns 44,250 shares in the company, valued at $1,036,335. The disclosure for this purchase can be found here. 14.59% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Stifel Financial Corp purchased a new position in shares of Flexion Therapeutics in the 1st quarter worth about $293,000. Redmile Group LLC raised its position in shares of Flexion Therapeutics by 33.5% in the 2nd quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after purchasing an additional 3,330 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Flexion Therapeutics by 22.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after purchasing an additional 2,960 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Flexion Therapeutics in the 1st quarter worth about $381,000. Finally, Wexford Capital LP purchased a new position in shares of Flexion Therapeutics in the 1st quarter worth about $401,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: Google Finance Portfolio

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply